C. Yurdaydin Et Al. , "Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B," 41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver , vol.44, Vienna, Austria, 2006
Yurdaydin, C. Et Al. 2006. Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B. 41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver , (Vienna, Austria).
Yurdaydin, C., Senturk, H., Boron-Kaczmarska, A., Raptopoulou-Gigi, M., Batur, Y., Goodman, Z., ... Vaughan, J.(2006). Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B . 41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, Austria
Yurdaydin, C. Et Al. "Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B," 41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, Austria, 2006
Yurdaydin, C. Et Al. "Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B." 41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver , Vienna, Austria, 2006
Yurdaydin, C. Et Al. (2006) . "Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B." 41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver , Vienna, Austria.
@conferencepaper{conferencepaper, author={C. Yurdaydin Et Al. }, title={Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B}, congress name={41st Annual Meeting of the European-Association-for-the-Study-of-the-Liver}, city={Vienna}, country={Austria}, year={2006}}